AUTHOR=He Guixin , Ge Ting , Wang Baohui , Yu Jianchun , Li Wentao 

TITLE=Immune indicators as predictors of cancer-related fatigue: a risk prediction model in pan-cancer patients

JOURNAL=Frontiers in Aging

VOLUME=Volume 6 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2025.1666116

DOI=10.3389/fragi.2025.1666116

ISSN=2673-6217

ABSTRACT=BackgroundCancer‐related fatigue (CRF) is a prevalent and multifactorial symptom that significantly impairs the quality of life in cancer patients. This study aimed to identify immune and clinical factors associated with CRF in a pan-cancer cohort and to develop a predictive model for CRF to inform personalized clinical management.MethodsA retrospective analysis was conducted on clinical data from 146 cancer patients admitted to the Oncology Department of the First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine. The variables collected included demographic information, disease‐related data, immunological parameters, and Brief Fatigue Inventory (BFI) scores. Univariate and multivariate logistic regression analyses were used to identify independent risk factors for CRF. A predictive model was developed, and its performance was evaluated using receiver operating characteristic (ROC) curve analysis and decision curve analysis.ResultsAnalysis results showed that multivariate logistic regression identified increasing age, increased absolute counts (AC) of CD4+CD38−T cells, and decreased AC of CD4+CD28−T cells as independent risk factors for CRF (P < 0.05). The predictive model demonstrated moderate performance, with an area under the ROC curve (AUC) of 0.725 in the training set and 0.581 in the validation set.ConclusionThese findings suggest that chronic inflammation, potentially associated with immunosenescence and immune remodeling, may contribute to the onset of CRF. Further research is needed to validate the model in large-scale, diverse patient populations and to develop targeted interventions to alleviate fatigue and improve the quality of life in cancer patients.